Patents Assigned to Epitracker, Inc.
  • Patent number: 12440473
    Abstract: Compositions comprising fatty acid analogs are provided for treating conditions involving impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, and convulsion, and other conditions. Methods for the diagnosis and monitoring of impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, convulsion, and other conditions are also provided.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: October 14, 2025
    Assignee: Epitracker, Inc.
    Inventor: Stephanie Venn-Watson
  • Patent number: 12427179
    Abstract: Compositions including small molecule biochemicals, and salts and derivatives thereof, and methods for detection, treatment or prophylaxis of neurodegenerative diseases are provided, including compositions and methods for detecting and treating conditions that contribute to neurodegenerative diseases, including peripheral and central inflammation, amyloid-? plaque deposition in the brain, neuronal iron deposition and hyperglycemia.
    Type: Grant
    Filed: July 8, 2021
    Date of Patent: September 30, 2025
    Assignee: Epitracker, Inc.
    Inventor: Stephanie Venn-Watson
  • Patent number: 12370166
    Abstract: Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipolar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pai
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: July 29, 2025
    Assignee: Epitracker, Inc.
    Inventor: Stephanie Venn-Watson
  • Patent number: 11992473
    Abstract: Compositions including metabolites that are small molecules, and salts and derivatives thereof, and methods for treatment or prophylaxis of conditions related to the quality of aging are provided, including compositions and methods for treating conditions that negatively impact longevity and the quality of aging, including inflammation, anemia, hyperglycemia, dyslipidemia, hyperinsulinemia, liver disease, iron overload, impaired skin integrity, wound healing, scarring, pain, allergies, sleep disorders and problems, and gastrointestinal disorders and problems.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: May 28, 2024
    Assignee: Epitracker, Inc.
    Inventor: Stephanie Venn-Watson
  • Patent number: 11951088
    Abstract: Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: April 9, 2024
    Assignee: EPITRACKER, INC.
    Inventors: Stephanie Venn-Watson, John Reiner, Richard Lumpkin
  • Patent number: 10792266
    Abstract: Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 6, 2020
    Assignee: Epitracker, Inc.
    Inventors: Stephanie Venn-Watson, John Reiner, Richard Lumpkin